Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elevation Oncology, Inc.

0.3817
+0.00150.39%
Post-market: 0.3800-0.0017-0.45%19:41 EDT
Volume:801.88K
Turnover:304.97K
Market Cap:22.62M
PE:-0.47
High:0.3851
Open:0.3755
Low:0.3755
Close:0.3802
Loading ...

Bml Investment Partners Lp Reports 9.9% Stake in Elevation Oncology Inc as of April 16 - SEC Filing

THOMSON REUTERS
·
16 Apr

BRIEF-Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing

Reuters
·
05 Apr

Elevation Oncology Inc - to Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing

THOMSON REUTERS
·
05 Apr

Elevation Oncology’s Chief Medical Officer Steps Down

TIPRANKS
·
02 Apr

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

PR Newswire
·
26 Mar

Elevation Oncology Cut to Equal-Weight From Overweight by Stephens & Co.

Dow Jones
·
24 Mar

Stephens Downgrades Elevation Oncology to Equal Weight From Overweight, Adjusts Price Target to $1 From $5

MT Newswires Live
·
24 Mar

Elevation Oncology downgraded to Equal Weight from Overweight at Stephens

TIPRANKS
·
24 Mar

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Zacks
·
22 Mar

Elevation Oncology downgraded as it halts lead asset on disappointing trials

Investing.com
·
22 Mar

Elevation Oncology Cut to Neutral From Overweight by Piper Sandler

Dow Jones
·
21 Mar

Elevation Oncology Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
21 Mar

Piper Sandler Downgrades Elevation Oncology to Neutral From Overweight, Adjusts Price Target to $0.70 From $10

MT Newswires Live
·
21 Mar

Elevation Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
21 Mar

Elevation Oncology downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
21 Mar

Elevation Oncology’s Strategic Shift and Financial Stability Justify Hold Rating

TIPRANKS
·
21 Mar

Elevation Oncology downgraded to Market Perform from Outperform at Citizens JMP

TIPRANKS
·
21 Mar

U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose

Reuters
·
21 Mar

Elevation Oncology Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $1 From $9

THOMSON REUTERS
·
21 Mar

Elevation Oncology Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $0.70 From $10

THOMSON REUTERS
·
21 Mar